Zemcelpro Gains Ground in Germany: A Turning Point for Stem Cell Therapy
ExCellThera and its subsidiary, Cordex Biologics, have secured a significant regulatory milestone with the NUB (Neue Untersuchungs- und Behandlungsmethoden) Status 1 listing in Germany for Zemcelpro (dorocubicel), also known as UM171 Cell Therapy. This designation paves the way for hospitals across Germany to seek temporary, supplementary reimbursement for the treatment, accelerating access for patients in need.
What is NUB Status 1 and Why Does it Matter?
The NUB program in Germany is designed to support the introduction of innovative medical treatments. Achieving Status 1 signifies that Zemcelpro is backed by a growing body of clinical evidence. This allows German hospitals to apply for funding to cover the cost of the therapy while longer-term reimbursement pathways are established. Notably, over 220 hospitals have already expressed interest in utilizing Zemcelpro through this mechanism in 2026.
A Lifeline for Patients with Limited Options
Zemcelpro is a cryopreserved haematopoietic stem cell therapy intended for adults with life-threatening blood cancers who require allogeneic haematopoietic stem cell transplantation but lack suitable donor cells. This addresses a critical unmet need in the treatment of haematological malignancies. Clinical trials involving more than 120 patients across Canada, Europe, and the US have contributed to the growing clinical evidence supporting its use.
European Commission Approval and Global Expansion
This NUB Status 1 listing follows the European Commission’s conditional marketing authorization granted in 2025. ExCellThera is now actively planning regulatory submissions for Zemcelpro in the US, Canada, Switzerland, and the UK. The company is also forging strategic partnerships to support the global commercialization of this potentially life-saving therapy.
How Zemcelpro Works: A Closer Look
Zemcelpro is composed of UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, all sourced from a single cord blood unit. This innovative approach aims to provide a viable stem cell source for patients who would otherwise be unable to undergo transplantation.
The Future of Allogeneic Stem Cell Transplantation
The approval of Zemcelpro and its progress through regulatory pathways signal a broader trend towards more accessible and innovative stem cell therapies. The challenges of finding suitable donors for allogeneic transplants are well-documented, and therapies like Zemcelpro offer a potential solution. The success of the NUB program in Germany could serve as a model for other countries looking to accelerate the adoption of cutting-edge treatments.
Post-Market Data and Clinical Guidelines
Cordex Biologics plans to collaborate with German transplant centers on NUB applications and actively participate in post-market registries. This data collection will be crucial for securing long-term reimbursement and integrating Zemcelpro into established clinical guidelines.
Frequently Asked Questions
What is allogeneic haematopoietic stem cell transplantation? It’s a procedure where stem cells from a donor are used to replace a patient’s damaged or diseased bone marrow.
What does ‘conditional marketing authorization’ mean? It means the therapy is approved for use while further data is collected to confirm its long-term benefits.
What is cord blood? Cord blood is the blood that remains in the umbilical cord after birth, and We see a rich source of stem cells.
What is the NUB program? The NUB program is a German initiative to support the introduction of new and innovative medical treatments.
Pro Tip: Patients interested in learning more about Zemcelpro should discuss it with their hematologist or transplant specialist to determine if it’s a suitable treatment option.
Did you know? Finding a perfectly matched donor for stem cell transplantation can be challenging, with only about 30% of patients finding a fully matched sibling donor.
Stay informed about the latest advancements in stem cell therapy and cancer treatment. Explore more articles on our site or subscribe to our newsletter for regular updates.